Interestingly, mutations in KCNA1 are considered to be potential biomarkers for sudden unexpected death in epilepsy patients (SUDEP), thus further highlighting the prospective benefit of Kv1.1-targeted therapeutic approaches [59,60]. The gene discussed is KCNA1; the disease is epilepsy.